AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial

The University of Minnesota’s Center for Infectious Disease Research & Policy (CIDRAP) has reported that AstraZeneca‘s monoclonal antibody combination drug, Evusheld, failed to improve outcomes in a Phase III trial involving hospitalised Covid-19 patients.